Cardiovascular Risk Assessment in the Treatment of Nonalcoholic Steatohepatitis: A Secondary Analysis of the MOZART Trial

Therapeutic Advances in Gastroenterology - United Kingdom
doi 10.1177/1756283x15621232
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)

Hepatology
MedicineHepatology
2015English

The Epidemiology of Nonalcoholic Steatohepatitis

Clinical Liver Disease
Hepatology
2018English

Cost-Utility Analysis of Nonalcoholic Steatohepatitis Screening

European Radiology
MedicineNuclear MedicineRadiologyImaging
2015English

Pathophysiology of Nonalcoholic Steatohepatitis

Juntendo Medical Journal
2017English

Nonalcoholic Steatohepatitis

English

Cyclophilin Inhibition as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)

Expert Opinion on Investigational Drugs
MedicinePharmacology
2019English

A New Mechanism of Lipotoxicity: Calcium Channel Blockers as a Treatment for Nonalcoholic Steatohepatitis?

Hepatology
MedicineHepatology
2015English

The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

Journal of Clinical and Experimental Hepatology
Hepatology
2015English

The Art of Cardiovascular Risk Assessment

Clinical Cardiology
MedicineCardiovascular MedicineCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy